{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:16:20Z","timestamp":1785842180919,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/igc.0b013e31821e052e","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T04:29:16Z","timestamp":1311654556000},"page":"1040-1047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients"],"prefix":"10.1016","volume":"21","author":[{"given":"Karina Dahl","family":"Steffensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Waldstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Brandslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e31821e052e_bb0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/02841861003691945","article-title":"Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964\u20132003 followed up to the end of 2006","volume":"49","author":"Klint","year":"2010","journal-title":"Acta Oncol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ctrv.2006.01.001","article-title":"Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer","volume":"32","author":"Serrano-Olvera","year":"2006","journal-title":"Cancer Treat Rev."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cncr.11476","article-title":"Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study","volume":"98","author":"Hogdall","year":"2003","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2003.10.010","article-title":"ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma","volume":"92","author":"Lassus","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0030","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.bjc.6601961","article-title":"Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)","volume":"91","author":"Elie","year":"2004","journal-title":"Br J Cancer."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0035","first-page":"154","article-title":"HER2\/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance","volume":"68","author":"Verri","year":"2005","journal-title":"Clinical study. Oncology."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0040","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ijgc-00009577-200707000-00008","article-title":"The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer","volume":"17","author":"Steffensen","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0045","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ijgc-00009577-200411000-00005","article-title":"Prognostic significance of p53, HER-2, and EGFR overexpression in borderline and epithelial ovarian cancer","volume":"14","author":"Nielsen","year":"2004","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2559.2005.02306.x","article-title":"HER-2\/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays","volume":"48","author":"Mayr","year":"2006","journal-title":"Histopathology."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001138","article-title":"HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients","volume":"2","author":"Tuefferd","year":"2007","journal-title":"PLoS ONE."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-8258(03)00192-6","article-title":"Risk of malignancy index in the preoperative evaluation of patients with adnexal masses","volume":"90","author":"Andersen","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0070","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1471-0528.1996.tb09882.x","article-title":"Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses","volume":"103","author":"Tingulstad","year":"1996","journal-title":"Br J Obstet Gynaecol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.05.001","article-title":"Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer","volume":"69","author":"Gadducci","year":"2009","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-2215-2-13","article-title":"Role of CA125 in predicting ovarian cancer survivalVa review of the epidemiological literature","volume":"2","author":"Gupta","year":"2009","journal-title":"J Ovarian Res."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0085","first-page":"5007","article-title":"Identification by cDNA microarray of genes involved in ovarian carcinogenesis","volume":"60","author":"Ono","year":"2000","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0090","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1073\/pnas.98.3.1176","article-title":"Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer","volume":"98","author":"Welsh","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0095","first-page":"5895","article-title":"Genetic analysis of early-versus late-stage ovarian tumors","volume":"61","author":"Shridhar","year":"2001","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(99)00035-9","article-title":"Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray","volume":"229","author":"Wang","year":"1999","journal-title":"Gene."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj20020869","article-title":"A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein","volume":"368","author":"Clauss","year":"2002","journal-title":"Biochem J."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(06)70579-4","article-title":"Proteins with whey-acidic-protein motifs and cancer","volume":"7","author":"Bouchard","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0120","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e31821e052e_bb0125","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24045614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24045614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.lww.com\/ijgc\/Fulltext\/10.1097\/IGC.0b013e31821e052e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:35:47Z","timestamp":1753101347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24045614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1048891X24045614"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e31821e052e","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e31821e052e","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2011 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}